Indivior/$INDV
1D1W1MYTD1Y5YMAX
About Indivior
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).
- Ticker
- $INDV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 833
- Headquarters
- North Chesterfield, United States
- Website
- www.indivior.com
Indivior Metrics
BasicAdvanced
$4.1B
12.59
$2.77
1.14
-
Price and volume
Market cap
$4.1B
Beta
1.14
52-week high
$42.81
52-week low
$27.68
Average daily volume
2.3M
Financial strength
Current ratio
0.835
Quick ratio
0.586
Long term debt to equity
-240.385
Total debt to equity
-244.712
Interest coverage (TTM)
20.74%
Profitability
EBITDA (TTM)
576
Gross margin (TTM)
85.57%
Net profit margin (TTM)
26.75%
Operating margin (TTM)
42.07%
Effective tax rate (TTM)
9.64%
Revenue per employee (TTM)
$1,600,000
Management effectiveness
Return on assets (TTM)
26.07%
Return on equity (TTM)
-153.12%
Valuation
Price to earnings (TTM)
12.585
Price to revenue (TTM)
3.232
Price to book
-19.76
Price to tangible book (TTM)
-19.57
Price to free cash flow (TTM)
-38.752
Free cash flow yield (TTM)
-2.58%
Free cash flow per share (TTM)
-0.899
Growth
Revenue change (TTM)
13.47%
Earnings per share change (TTM)
227.70%
3-year revenue growth (CAGR)
9.93%
10-year revenue growth (CAGR)
2.62%
3-year earnings per share growth (CAGR)
86.01%
10-year earnings per share growth (CAGR)
8.26%
Indivior News
AllArticlesVideos
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire6 days ago
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc. - SUPN
Business Wire4 weeks ago
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.